What is the role of ultrafast-acting insulin in the treatment of type 1 diabetes mellitus (DM)?

Updated: Sep 13, 2019
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print
Answer

An ultrafast-acting insulin aspart formulation for mealtimes (Fiasp), for adult patients with type 1 or 2 DM, was approved in January 2017 for use in Canada and the Europe Union. The drug contains conventional mealtime insulin aspart in combination with two ingredients—vitamin B3 and the amino acid L-arginine—that are meant to allow faster insulin absorption so the medication can better mimic natural physiologic insulin. Unlike in the European Union, however, the new formulation is not approved for insulin pumps in Canada. The product has not yet been approved for use in the United States. [113]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!